Vaxxas has received a manufacturing licence from Australia’s Therapeutic Goods Administration (TGA) for its high-density microarray patch (HD-MAP) for clinical studies at a biomedical facility in ...

Vaxxas Chair Sarah Meibusch said, "The TGA manufacturing licence marks a significant milestone for Vaxxas as we progress toward commercialising our HD-MAP technology. By reducing cold-chain ...

A recent study on DNA microarray technology highlights its essential role in enabling high-throughput analysis of large numbers of genes through arrays of probes integrated on a solid-phase support.

As genetic analysis expands to serve everything from population-scale studies to precision-driven clinical decisions, laboratories are under growing pressure to move faster while managing increasingly ...

New SwiftArrayStudio analyzer and updated genotyping arrays deliver results in as little as 30 hours, enabling researchers to drive impactful, scalable genetic research Thermo Fisher Scientific, the ...

The MarketWatch News Department was not involved in the creation of this content. -- Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via "patch" technology and utilizes ...

Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via “patch” technology and utilizes Micron’s first-in-class dissolvable microarray technology Research builds on Emory’s ...

Reported Data Supports the Potential Extension of HD-MAP Vaccine Delivery to Oncology Indications Recently published data generated by researchers at The University of Queensland and Vaxxas shows ...

[Image from Micron Biomedical website] Micron Biomedical announced today that it added $16 million in funding to bring its Series A equity round to more than $33 million. J2 Ventures and the Global ...